Chronic kidney disease

@article{KalantarZadeh2021ChronicKD,
  title={Chronic kidney disease},
  author={K. Kalantar-Zadeh and T. Jafar and D. Nitsch and B. Neuen and V. Perkovic},
  journal={The Lancet},
  year={2021},
  volume={398},
  pages={786-802}
}
Chronic kidney disease is a progressive disease with no cure and high morbidity and mortality that occurs commonly in the general adult population, especially in people with diabetes and hypertension. Preservation of kidney function can improve outcomes and can be achieved through non-pharmacological strategies (eg, dietary and lifestyle adjustments) and chronic kidney disease-targeted and kidney disease-specific pharmacological interventions. A plant-dominant, low-protein, and low-salt diet… Expand

References

SHOWING 1-10 OF 218 REFERENCES
Diabetic Kidney Disease: Challenges, Progress, and Possibilities.
TLDR
Widespread innovation is urgently needed to improve health outcomes for patients with diabetic kidney disease, and characterization of new biomarkers, designing clinical trials that evaluate clinically pertinent end points, and development of therapeutic agents targeting kidney-specific disease mechanisms are needed. Expand
Chronic Kidney Disease
TLDR
Diagnosis is commonly made after chance findings from screening tests (urinary dipstick or blood tests), or when symptoms become severe, and the best available indicator of overall kidney function is GFR, which is measured either via exogenous markers (eg, DTPA, iohexol), or estimated using equations. Expand
Hypertension in CKD: Core Curriculum 2019.
TLDR
Althoughintensive BP control has not been shown in clinical trials to slow the progression of CKD, intensive BP control reduces the risk for adverse cardiovascular outcomes and mortality in the CKD population. Expand
The global burden of chronic kidney disease
TLDR
The GBD data are a stark confirmation that the global burden of CKD is increasingly carried by countries in low and middle Socio-demographic Index (SDI) quintiles, with an epidemiological shift in mortality from communicable diseases to non-communicable diseases, with major increases in the prevalence of diabetes and hypertension. Expand
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
TLDR
There is a rationale for studying the cardio-renal effects of SGLT-2 inhibition in people at risk of CV disease and hyperfiltration, irrespective of whether they have diabetes. Expand
Novel conservative management of chronic kidney disease via dialysis-free interventions
TLDR
As dialysis may not confer better survival nor improved patient-centered outcomes in certain patients, conservative management is a viable treatment option in the advanced CKD population. Expand
Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins.
TLDR
The gut microbiome is a major contributor to adverse cardiovascular outcomes and progression of CKD and the evidence supporting a role for gut-derived uremic toxins in promoting multiorgan dysfunction via inflammatory, oxidative stress, and apoptosis pathways is discussed. Expand
Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review.
TLDR
This summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference on CAD and CKD seeks to improve understanding of the epidemiology, pathophysiology, diagnosis, and treatment of CAD in CKD and to identify knowledge gaps, areas of controversy, and priorities for research. Expand
Plant-Dominant Low-Protein Diet for Conservative Management of Chronic Kidney Disease
TLDR
Evidence suggests that a patient-centered plant-dominant low-protein diet (PLADO) of 0.6–0.8 g/kg/day composed of >50% plant-based sources, administered by dietitians trained in non-dialysis CKD care, is promising and consistent with the precision nutrition. Expand
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
TLDR
The relative risk reduction for the primary composite outcome with dapagliflozin was consistent in participants with type 2 diabetes and those without diabetes, with similar consistency seen across the secondary outcomes. Expand
...
1
2
3
4
5
...